| Date | Title | | | 01/18/12 | Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline| NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 18, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23, 2012 at 8:30 am Eastern Time. The event will provide updates on the Company’s robust pipeline in oncology and cancer immunotherapy, featuring presentations from leading researchers and investigators as well as Celldex management. For information on attending the event, please contact Sarah C... |
|  | | 01/17/12 | Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301| NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 17, 2012--
Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing
has initiated in a Phase 1 study of its hematopoietic growth factor,
CDX-301, in healthy subjects. The study is being conducted in
collaboration with Rockefeller University. CDX-301 is soluble,
recombinant human FMS-like tyrosine kinase 3 ligand (Flt3L) and previous
experience has shown that it increases the numbers and activity of b... |
| | | 01/04/12 | Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations| - Vaccine Targets Patients with EGFRvIII-positive Recurrent Glioblastoma -
NEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 4, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that patient screening has initiated in a Phase 2 trial of rindopepimut in combination with Avastin® in patients with recurrent epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, called the “ReACT Study.” This new study will run in parallel with Celldex’s Phase 3 trial (ACT IV) evaluating rindopep... |
| | | 12/21/11 | Celldex Completes Accrual of CDX-011 Phase 2b “EMERGE” Study in Advanced Breast Cancer| NEEDHAM, Mass.--(BUSINESS WIRE)--Dec. 21, 2011--
Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it has
completed accrual of the EMERGE study, a randomized Phase 2b study
evaluating CDX-011 (glembatumumab vedotin) in patients with previously
treated metastatic or locally advanced breast cancer. The Company
anticipates presenting results at an appropriate scientific conference
in the first half of 2012.
“The median surviv... |
| |
|
